Licensing agreement with Medinfar and protocol available to the scientific community
Serology4COVID Consortium led by the Instituto Gulbenkian de Ciência, which brings together iBET, CEDOC-NMS, iMM and ITQB-NOVA closed licensing agreement for the serological tests to Medinfar, leader in the areas of Consumer Healthcare and Dermatology.
At the same time, the consortium guarantees access to the knowledge produced, making the protein and the respective protocol available to Research Centers in Portugal and in Portuguese Speaking African Countries (PALOP) interested in developing academic studies on the SARS-CoV-2 virus (including conducting serological studies on the respective employees of the institutions).
The serological test developed by the consortium was initially applied in several academic studies promoted by the consortium partners:
- 8000 tests carried out by IGC in the scope of the pilot project with the Almeirim City Council and in the monitoring project of 1500 health professionals, started in April;
- 3500 tests carried out by iMM under the COVID-19 test campaign carried out by the University of Lisbon and projects with the Centro Hospitalar Lisboa Norte, the Faculty of Medicine and the Instituto Português do Sangue e Transplantação;
- 1645 by CEDOC-NMS in the scope of Serological Screening to the community of Universidade NOVA de Lisboa.
Serology4COVID fulfills its purpose: to develop a scalable and economical serological test for COVID-19, entirely made in Portugal, a strategic tool to learn about the expansion of immunity in the population and support the implementation of measures to control the disease with a view to minimizing the consequences of this pandemic on health, society, and the economy.
The Consortium received financial support from the Covid-19 Emergency Fund of the Calouste Gulbenkian Foundation, from the Francisco Manuel dos Santos Society and the Oeiras City Council.
Request the protocol and protein
All research centers, in Portugal and in Portuguese Speaking African Countries (PALOP), who want to develop SARS-CoV-2 virus research projects and/or test their own collaborators, can request access to the protocol and the protein.
To do so, they must:
- Fill out the Material Transfer Agreement available here;
- Submit the Material Transfer Agreement (in pdf) by email to: [email protected]
- After submission, the application will be evaluated (applicant, the context of the study, and according to protein availability)
- Response will be sent, by the same means, and delivery logistics will be defined, the costs of which will be supported by the receiving entity.
To know more about the Serology4COVID Consortium